Abstract: A biological information measurement device includes a heart rate counting unit for measuring an HR value indicating a heart rate on a basis of heart-rate data obtained by capturing heartbeats when a subject to be measured exercises, an analysis unit for performing power spectrum analysis on a heart rate variability frequency of the heart-rate data to calculate an LF value which is an integral value of low frequency components, and a detection unit for obtaining an HR/LF value by dividing the HR value by the LF value with respect to exercise intensity of the subject to be measured.

Abstract: Provided is a cell sheet support that satisfactory adheres to cultured cell and has biodegradability. The cell sheet support contains a first polymer containing a structural unit derived from p-dioxanone. The cell sheet support further contains a second polymer containing at least one selected from the group consisting of polylactic acid, polyglycolic acid, polycaproic acid, and copolymers thereof. The content ratio of the first polymer to the total amount of the first polymer and the second polymer is not less than 50% by mass. The cell sheet support has a sheet shape having an average thickness of 10 ?m to 150 ?m.

Abstract: Provided is an oligonucleotide which may induce an editing activity of ADRC in cell and has excellent stability in a living body. The oligonucleotide includes a first oligonucleotide identifying a target RNA and a second oligonucleotide linked to the 5?-side of the first oligonucleotide. The first oligonucleotide consists of a target-corresponding nucleotide residue, an oligonucleotide of 10 to 24 residues at the 3?-side, and an oligonucleotide of 3 to 6 residues at the 5?-side. The second oligonucleotide has no nucleotide residue corresponding to a nucleotide residue of the target RNA or has a nucleotide residue which does not form a complementary pair at the 3?-end thereof and the number of residue is 3 to 6.

Abstract: A bubble manufacturing container of the present invention includes: a container body having an opening portion; and a rubber stopper provided on the opening portion of the container body. The rubber stopper is constituted so that the bubbles 1 of an inside of the container body are able to be taken by piercing an injection needle. It is preferred that the bubble manufacturing container has a fastening portion provided on the rubber stopper, having an opening and sealing the container body with the rubber stopper. Furthermore, it is preferred that the container body mounts a weight portion.

Abstract: Provided is a method for modifying a polypropylene resin molded body with a side chain crystalline block copolymer having a long alkane chain in a side chain, having a good interaction force with the polypropylene resin molded body, and having a function capable of modifying surface characteristics. Also provided is a modified polypropylene resin molded body. The method for modifying a polypropylene resin molded body includes a step of contacting a copolymer solution including a side chain crystalline block copolymer with a polypropylene resin molded body at a temperature of the copolymer solution of 40 to 120° C. The modified polypropylene resin molded body includes a base material of the polypropylene resin molded body and a site that includes the side chain crystalline block copolymer in at least part of the base material.

Abstract: Provided is a short-chain guide RNA that is able to induce site-specific editing even when only a small number of nucleotides is attached to the target recognition site. The guide RNA includes a first oligonucleotide that identifies the target RNA, and a second oligonucleotide that links to the 3? end of the first oligonucleotide. The first oligonucleotide contains: a target-corresponding nucleotide residue that corresponds to an adenosine residue in the target RNA; an oligonucleotide of 15 to 30 residues that links to the 5? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA; and an oligonucleotide of 3 or 4 residues that links to the 3? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA. The second oligonucleotide contains 2 to 24 nucleotide residues, and induces site-specific editing of the target RNA.

Abstract: Provided is a short-chain guide RNA that is able to induce site-specific editing even when only a small number of nucleotides is attached to the target recognition site. The guide RNA includes a first oligonucleotide that identifies the target RNA, and a second oligonucleotide that links to the 3? end of the first oligonucleotide. The first oligonucleotide contains: a target-corresponding nucleotide residue that corresponds to an adenosine residue in the target RNA; an oligonucleotide of 15 to 30 residues that links to the 5? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA; and an oligonucleotide of 3 or 4 residues that links to the 3? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA. The second oligonucleotide contains 2 to 24 nucleotide residues, and induces site-specific editing of the target RNA.

Abstract: An object of the present invention is to find a useful means for removing an intraocular membrane. The present invention relates to an agent for use in intraocular membrane peeling surgery, which contains a solution containing a hydrogel-forming material and satisfies the following formula 1 with respect to the dynamic viscoelasticity measured at a temperature of 25 to 40° C. and a frequency of 1 Hz. 0<Vmax?3??(Formula 1) Provided that in the formula 1, Vmax (Pa/sec) is the maximum change rate of the storage elastic modulus after the initiation of gelation.

Abstract: An oligonucleotide that induces a site-specific editing for a target RNA, the oligonucleotide including a first oligonucleotide that specifies the target RNA, a second oligonucleotide that is linked to the 3?-side of the first oligonucleotide, a third oligonucleotide that is capable of forming a complementary pair together with the second oligonucleotide, and a first linking portion that links the second oligonucleotide and the third oligonucleotide. The first oligonucleotide is composed of a target-corresponding nucleotide residue that corresponds to an adenosine residue in the target RNA; an oligonucleotide of 10 to 30 residues linked to the 5?-side of the target-corresponding nucleotide residue and having a base sequence complementary to the target RNA; and an oligonucleotide of 3-6 residues linked to the 3?-side of the target-corresponding nucleotide residue and having a base sequence complementary to the target RNA.

Abstract: [Problem to be Solved] To provide a guide RNA. [Solution] A guide RNA for editing a target RNA sequence, comprising an antisense nucleotide sequence complementary to a portion of the target RNA sequence, a short-chain ADAR-recruiting nucleotide sequence, and at least one functional nucleotide sequence.

Abstract: An object of the present invention is to provide a pharmaceutical composition containing mesenchymal stem cells that exhibit excellent therapeutic effects on various diseases, injured parts, wounds and decubitus. The present invention relates to a pharmaceutical composition for treating a non-porcine animal, the pharmaceutical composition includes a neonatal pig-derived mesenchymal stem cell which produces at least one humoral factor selected from TGF-?1, TGF-?2, VEGF-A and VEGF-C.

Abstract: A method for inducing a site-directed RNA mutation is provided. The method includes repairing an RNA mutation by converting target adenosine, which is located at a target editing site of a target RNA, into inosine. The method for inducing a site-directed RNA mutation involves reacting the target RNA having a target adenosine with a target editing guide, which has been constructed so as to form a complementary strand with target RNA, to form a double-stranded complex, and converting the target adenosine to inosine by causing ADAR to act on the double-stranded complex, inducing A-to-I editing capability. The converted inosine is further translated into guanosine.

Abstract: The present invention addresses the problem of providing, by a method in which an expensive manufacturing apparatus is not required, an implant material having osteoconductivity superior to that of an implant material containing an aromatic polyether ketone. The present invention pertains to: said method including immersing an aromatic polyether ketone in a strong base solution in the absence of a calcium ion, and immersing an aromatic polyether ketone, which is obtained by the immersing, in a liquid containing a phosphorus-containing compound; and an implant material obtained by said method.

Abstract: A composition for inhibiting the formation of hypertrophic scar, comprising at least one of a polypeptide consisting of an amino acid sequence having a dipeptide sequence represented by Pro-Hyp or Hyp-Gly, a chemically-modified form thereof, or a pharmaceutically acceptable salt thereof.

Abstract: A bubble manufacturing container 20 of the present invention includes: a container body 21 having an opening portion; and a rubber stopper 221 provided on the opening portion of the container body 21. The rubber stopper 221 is constituted so that the bubbles 1 of an inside of the container body 21 are able to be taken by piercing an injection needle. It is preferred that the bubble manufacturing container 20 has a fastening portion 222 provided on the rubber stopper 221, having an opening and sealing the container body 21 with the rubber stopper 221. Furthermore, it is preferred that the container body 21 mounts a weight portion.

Abstract: Provided is a short-chain guide RNA that is able to induce site-specific editing even when only a small number of nucleotides is attached to the target recognition site. The guide RNA includes a first oligonucleotide that identifies the target RNA, and a second oligonucleotide that links to the 3? end of the first oligonucleotide. The first oligonucleotide contains: a target-corresponding nucleotide residue that corresponds to an adenosine residue in the target RNA; an oligonucleotide of 15 to 30 residues that links to the 5? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA; and an oligonucleotide of 3 or 4 residues that links to the 3? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA. The second oligonucleotide contains 2 to 24 nucleotide residues, and induces site-specific editing of the target RNA.

Abstract: Provided is a manufacturing apparatus that manufactures a high-quality manufacturing object by using component information per unit of individual electronic component or per unit of package in a plurality of electronic components that have been packaged. The manufacturing apparatus is a manufacturing apparatus that manufactures a product by taking out each electronic component from packaged components in which a plurality of electronic components are packaged.

Abstract: A pharmaceutical composition contains adipose tissue derived reproductive cells including adipose stem cells, vascular endothelial cells and vascular pericytes. The composition is administrated into an intrauterine cavity of a subject and used for treatment of infertility. A method for producing the pharmaceutical composition includes treating an adipose tissue with a disaggregation agent to obtain a disaggregated tissue; concentrating reproductive cells from the disaggregated tissue by centrifugal separation treatment; and recovering concentrated reproductive cells. A method for treatment of infertility of a subject includes administering a pharmaceutical composition into an intrauterine cavity of a subject. The pharmaceutical composition contains adipose tissue derived reproductive cells including adipose stem cells, vascular endothelial cells and vascular pericytes.

Abstract: To develop a clinically useful composition and an endoscopic observation method that utilizes WOS properties. The composition for improving diagnostic performance, containing lipids as a component is characterized in that, by administering or loading said composition orally, by intubation or via an endoscope, the lipids are absorbed by gastric tumors, facilitating the detection of tumors and qualitative diagnoses by endoscope. Tumors are thus whitened by administering or loading this composition for improving diagnostic performance prior to endoscopic observation, making it easier to discover and qualitatively diagnose tumors by endoscopic observation.

Abstract: [Problem] Provided are: an ultrasound-guided puncture assist device that is capable of preventing occurrence of operational mistakes or the like when a nerve block or vascular puncture is performed under ultrasonography, an ultrasound-guided puncture method using the ultrasound-guided puncture assist device, and the like. [Solution] An ultrasound-guided puncture assist device with an object of preventing narrowing or the like of a puncture target site for a nerve block or vascular puncture under ultrasonography to thereby assist the puncture by comprising a pulling mechanism for pulling the surface of the puncture target site, such as skin. The use of the ultrasound-guided puncture assist device of the invention can increase the width of the target site tissue where a nerve block or vascular puncture is performed, and thus occurrence of mispuncture is preventable.